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Abstract
Introduction and Purpose
Propidium monoazide (PMA)-pretreatment has increasingly been applied to remove the
bias from dead or damaged cell artefacts, which could impact the microbiota analysis by
high-throughput sequencing. Our study aimed to determine whether a PMA-pretreatment
coupled with high-throughput sequencing analysis provides a different picture of the airway
mycobiome and bacteriome.
Results and Discussion
We compared deep-sequencing data of mycobiota and microbiota of 15 sputum samples
from 5 cystic fibrosis (CF) patients with and without prior PMA-treatment of the DNA-
extracts. PMA-pretreatment had no significant effect on the entire and abundant bacterial
community (genera expressed as operational taxonomic units (OTUs) with a relative abun-
dance greater than or equal to 1%), but caused a significant difference in the intermediate
community (less than 1%) when analyzing the alpha biodiversity Simpson index (p = 0.03).
Regarding PMA impact on the airway mycobiota evaluated for the first time here; no signifi-
cant differences in alpha diversity indexes between PMA-treated and untreated samples
were observed. Regarding beta diversity analysis, the intermediate communities also dif-
fered more dramatically than the total and abundant ones when studying both mycobiome
and bacteriome. Our results showed that only the intermediate (or low abundance) popula-
tion diversity is impacted by PMA-treatment, and therefore that abundant taxa are mostly
viable during acute exacerbation in CF. Given such a cumbersome protocol (PMA-
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Introduction
Cystic fibrosis (CF) is associated with severe lung damage because of reduced mucociliary
clearance and subsequent polymicrobial infections [1]. Approximately 90% of CF patients suf-
fer from lung destruction, promoted by pathogens such as Pseudomonas aeruginosa. Conse-
quently, antibiotic treatment represents a keystone of CF therapy, preventing chronic
infection and reducing exacerbation rates and alteration of pulmonary function.
Until now, strategies to manage CF lung disease principally consist of routine microbiology
(including microbiological culture of sputum samples) and appropriate antibiotic treatment
[1,2]. While these conventional methods identify viable and abundant pathogens, they could
not detect uncultivable or difficult-to-cultivate microorganisms. The recent use of culture-
independent methods based on high-throughput sequencing (HTS) has provided a more com-
plete view of the CF lung bacterial microbiome and its evolution during respiratory alteration
[3–7]. However, the current use of HTS does not differentiate the DNA of living microorgan-
isms and that of dead microorganisms in sputum samples, which might be essential in the clin-
ical context of exacerbation. Sample pretreatment with propidium monoazide (PMA) might
facilitate viable microorganism detection, as recently proposed [6].
PMA is a chemical compound that selectively penetrates into cells with damaged mem-
brane (dead cells), intercalates covalently into their DNA and inhibits PCR amplification of
these dead microorganisms. It has been combined with different molecular methods to remove
bias from dead or damaged cell artefacts in microbial samples [6,8–17]. Exclusively several
studies have shown that the PMA cross-linking method leads to changes in the bacterial com-
munities using HTS [6,11–15].
The aim of the present study was to evaluate whether PMA-pretreatment associated with
HTS analysis is able to provide a more realistic profile of the viable fungal and bacterial commu-
nities in the CF airways, and consequently reflect more closely the clinical outcome of the
patients. We compared HTS data of pro- and eukaryotic microbiota obtained with and without
PMA-pretreatment of DNA extracts from sputum samples, in order to assess the impact of
PMA-pretreatment when quantifying the respiratory mycobiome and bacteriome of CF patients.
Materials and Methods
Ethics agreement
Ethics approval for this study was provided by the Ethics Committee of Ghent University Hos-
pital, Belgium (project nr. 2007/503). Study was performed in accordance with approved
national and international guidelines; written informed consent was obtained from all the
patients > 18 years or from the parents and children older than 12 years, as previously
reported [16,17].
Patients and sampling
Fifteen sputum samples were prospectively collected from 5 CF patients (3 homozygous and 2
heterozygous carriers of F508del-CFTR) followed at Ghent Hospital for acute pulmonary
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exacerbation. Patients aged from 15 to 34 years old, were chronically colonized with P. aerugi-
nosa [1], and received the same antimicrobial treatment: Tazocin1 (Piperacillin/Tazobactam
4000mg/500mg) by intravenous administration during 15 days. Sputum samples were col-
lected as previously reported [16,17].
PMA pretreatment
The PMA-pretreatment and DNA extractions were conducted at the laboratory for Bacteriol-
ogy Research of Ghent University as previously reported [16,17]. Briefly, each sputum sample
was transferred into 2 wells of a 24-well plate and 10 μl of PMA (final concentration: 50 mM)
(Biotium, Hayward, CA) was added to a first 190 μl sample aliquot (for PMA-qPCR) and 10 μl
saline buffer was added to the other sample aliquot. After 30 min incubation in the dark on a
shaker, the samples were exposed to a 500 W halogen light source for 10 min at a distance of
20 cm. During exposure, the 24-well plate was kept on ice to avoid overheating of the samples.
Culture-based quantification of P. aeruginosa [16,17]
Homogenized sputum samples were diluted serially tenfold in physiological saline. Each dilu-
tion (25μl) was inoculated in triplicate on cetrimide agar plates. The P. aeruginosa load was
determined after 72 h of incubation at 37˚C in ambient atmosphere.
Quantitative PCR targeting either P. aeruginosa or A. fumigatus
After DNA extraction using the easyMAG Nuclisens DNA extractor (bioMe´rieux, Marcy-
l’Etoile, France), qPCR was carried out on the Light-Cycler480 (Roche, Basel, Switzerland) as
previously described [16,17]. The reaction mixture contained 5 μl of Probes Master kit, 0.5 μM
of each primer (P. aeruginosa–oprL-gene forward: ACC CGA ACG CAG GCT ATG, reverse: CAG
GTC GGA GCT GTC GTA CTC), 0.1 μM of hydrolysis probe 6FAM-5’ AGAAGGTGGTGATCG
CACGCAGA3’-BlackBerry Quencher) and 2.5 μl of DNA-extract, for a final volume of 10 μl.
PCR annealing temperature was 55˚C. A standard tenfold dilution series was prepared using a
quantified DNA of P. aeruginosa strain PA14 for which the genome number was estimated
and translated into CFU. This standard dilution series was used in qPCR analysis to construct
a standard curve, which enabled to calculate the number of cells (in CFU) in the samples on
the basis of the obtained Ct-values.
The qPCR targeting A. fumigatus were performed for both PMA-treated and untreated
samples by real-time PCR performed with a 5-μl DNA volume on a LightCycler instrument
(Roche, Meylan, France), as previously described [18].
Metagenomic library preparation, sequencing and phylogenetic
assignation
The hypervariable V3–V5 regions of 16S-rRNA gene were amplified using the primers:
For16S_519, CAGCMGCCGCGGTAATACand the reverse primer Rev16S_926, CCGTCAATTC
MTTTGAGTTT. The ITS2 loci were amplified using the forward primer GATGAAGAACGYA
GYRAA, and reverse primer RBTTTCTTTTCCTCCGCT [19].
Indexed amplicon libraries were clonally amplified with Ion PGM™ Template OT2 400 Kit
and the Ion OneTouch™ ES Instrument (Ion Torrent), and sequenced through PGM, Ion Tor-
rent (Life Technologies).
Raw data analysis was performed using a home-made pipeline composed of open-source
softwares (Mothur [20], Esprit-tree [21], biome format [22]), databanks and home-made Perl/
python scripts, which were all implemented in Galaxy [23]. Briefly, the first step corresponded
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to a preprocessing step producing a curated and filtered collection of reads using Mothur tools
[20]. All reads shorter than 150 bases were removed. The remaining sequences were trimmed
to remove the erroneous homopolymers generated by the Ion Torrent PGM sequencer, with a
maximum limit for homopolymer length set to 20. Once this filtering was applied, duplicated
sequences were grouped to save computing time during the alignment and clustering steps.
The phylogenetic analysis was based on 16S rRNA gene classification from RDP, Silva and
GreenGene databases [24] and ITS2 gene classification from DBScreen database [25].
Sequences with alignments less than 100 bases were filtered out.
Statistical analyses
Data were considered as paired PMA-treated and untreated samples to study PMA impact in
the ecological characterization of a given sample. According to published data [26–28], fungal
and bacterial communities of each sample were divided into sub-populations as follows: Abun-
dant taxa were defined as genera with a relative OTU abundance greater than or equal to 1%
and intermediate taxa as having a relative abundance of less than 1%.
Alpha diversity indexes (richness, Shannon-Wiener and Simpson’s indexes) were compared
using Wilcoxon test. Beta diversity and OTU analysis were accessed using ANOSIM (analysis
of similarity) method, PCA (principal component analysis), and the Bray-Curtis similarity
index. To estimate similarity and changes in community composition of paired samples, we
applied a hierarchical cluster analysis based on the relative abundance of taxa in the samples
using Bray-Curtis similarity and a dendrogram inferred with the unweighted pair-group aver-
age algorithms. The clustering robustness was accessed by bootstrapping (10,000 replicates).
The p values were corrected using the Bonferroni correction for multiple comparisons.
Numerical variables were described as means and standard deviations or 95% confidence
interval. p-values of less than 0.05 were considered as significant. All statistical analyses were
performed using PAST software version 3.05 [29].
Results
Overall effect of PMA on the polymicrobial community in CF sputum
samples
The mean abundance of P. aeruginosa cells in PMA-untreated samples using qPCR (total
DNA, 7.44 ± 9.21 x 107 cells/ml) was significantly higher than that of PMA-treated samples
(5.17 ± 6.50 x 107 viable bacteria/ml; p = 0,00006 using pairwise t-test) and that of cultures
(2.91 ± 3.98 x 107 cells/ml), whereas P. aeruginosa abundances estimated by qPCR in PMA-
treated and culture samples were not statistically different (Fig 1). For each pair of samples,
qPCR results showed a regular positive difference between the two conditions, in agreement
with the expected PMA effect.
Regarding HTS raw data (ENA registered http://www.ebi.ac.uk/ena/data/view/
PRJEB14967, and S1 Table), the average total number of reads (both fungal plus bacterial
reads) of PMA-treated samples was slightly higher than that of untreated ones (respectively
176,135 ± 136,953 and 168,434 ± 178,433 reads). The mean length of sequences from PMA-
treated samples was shorter than that of untreated samples (respectively 323 ± 22 and 328 ± 16
bp) without any statistical significance.
For each sputum sample, we characterized the composition and diversity of fungal and bac-
terial microbiota. One and 5 pairs of samples were excluded from bacteriome and mycobiome
analysis respectively since corresponding rarefaction curves and/or numbers of reads were inad-
equate to allow biodiversity comparison. Therefore, among the 15 paired samples, only 14were
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analyzed at the bacterial NGS level and 10 at the mycological NGS level. The 14 paired samples
(n = 28) exhibited a total of 763,802 bacterial reads corresponding to 114 bacterial genera, and
the 10 paired samples (n = 20) exhibited 655,284 fungal reads corresponding to 90 fungal genera
(Figs 2 and 3). As the patient status regarding Aspergillus colonization was not expressly known,
we retrospectively assessed for A. fumigatus occurrence using qPCR in order to validate the
results of ITS2 deep sequencing-based method [18]. Only sputum samples from patient “G172”
exhibited positive PCR results at the limit of detection threshold (40.1 ± 2.1 Ct) [18,30].
The number of bacterial sequences in the samples ranged from 1,560 to 55,495 reads with
an average of 27279 ± 12673 (n = 28). The dominant genera co-presenting with Pseudomonas
(34.9%) were Streptococcus (27.4%), Azomonas (13.8%), Veillonella (6.6%), Prevotella (3.8%),
Porphyromonas (3.5%), Achromobacter (2.0%), Fusobacterium (1.3%) and Sneathia (1.1%) (Fig
3A). The mean number of fungal sequences was 32764 ± 39977 (n = 20). Dominant fungal
genera were Candida (70.5%), genus belonging to Saccharomycetes (13.0%), and Nakaseomyces
(11.3%) (Fig 3B).
Fig 1. Comparison of the enumeration of P. aeruginosa cells between cultures and qPCRs of PMA-
treated and untreated sputum samples.
doi:10.1371/journal.pone.0168860.g001
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The overall relative abundance of Pseudomonas genus increased from 27.8% in untreated
samples to 41.4% in PMA-treated ones (Fig 3A), while the species P. aeruginosa was decreased
after PMA-treatment, which may be linked to the antibiotic regimen (designed to kill P. aeru-
ginosa cells but not all the cells of genus Pseudomonas). Veillonella also increased from 4.3% to
8.8%, and Porphyromonas from 2.1% to 4.8%. By contrast, a number of genera decreased in
PMA-pretreated samples: in particular, the relative abundance of Streptococcus decreased from
29.3% to 25.5%, and that of Azomonas from 21.6% to 6.6%. The majority of these bacteria are
Fig 2. Venn diagram representing number of shared and specific bacterial (A) and fungal (B) genera
between PMA-treated and untreated samples. In each case, the first 5 most prevalent genera are listed.
doi:10.1371/journal.pone.0168860.g002
Fig 3. Global distribution of bacterial (A) and fungal (B) genera between PMA-treated (inner ring) and untreated
groups (outer ring). All genera are ordered in descending relative abundance.
doi:10.1371/journal.pone.0168860.g003
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described as susceptible to piperacillin/tazobactam. Regarding mycobiota overall data, the rela-
tive abundance of Candida and Nakaseomyces decreased from 71.5% to 69.7% and from 16.7%
to 6.9% respectively (Fig 3B).
Impact of PMA on biodiversity and similarity among fungal and bacterial
communities
PMA-treated and untreated groups shared 61 bacterial and 25 fungal genera (mostly referred
as dominant genera). While a majority of known bacterial and fungal pathogens were shared
by both types of samples (Fig 2), the bacterial or fungal genera referred as intermediate popula-
tions mainly belonged to the unshared populations (Figs 4A and 5A). For each sample pair,
HTS results were highly congruent between the two conditions (with and without PMA-pre-
treatment) excepted for samples G014-III, G176-III, and G088-II (Figs 4 and 5). The genus
numbers of both bacterial and fungal unshared populations were slightly higher in untreated
samples than in PMA-treated ones, as confirmed by means of richness and biodiversity
indexes (Table 1). More interestingly, we identified a significant difference in the intermediate
bacterial population based on Simpson index (p = 0.03) and a trend toward significance based
on Shannon index (p = 0.06) (Table 1). No significant differences in alpha diversity indexes of
mycobiota data were observed (Table 1).
Based on Bray-Curtis similarity calculation, the clustering of the entire communities (S1
Fig) was similar to the grouping of the abundant populations (S2 Fig) for both bacterial and
fungal microbiotas. Only 2 pairs of samples still exhibited such a similarity for their bacteriome
when the intermediate population was analyzed (S3 Fig).
PCA and outcome of the ANOSIM of the OTU data showed similar results: the paired sam-
ples (squares versus triangle in Figs 4B and 5B) still clustered relatively close to each other. The
main bacteria explaining the variance for the first axis in the PCA plots were from OTUs of
Prevotella, and of Pseudomonas, Streptococcus, Veillonella for the second axis (Fig 4B). The
principal fungi explaining the variance for the first axis were from OTUs of genera belonging
to Candida, Saccharomycetes, and Nakaseomyces. The main loadings of the second axis were
determined by those of Saccharomycetes (unknown order and genus) (Fig 5B). ANOSIM
method confirmed these findings, showing no significant differences between the PMA-
treated sample data and the untreated ones (Table 2). These beta-diversity results are consis-
tent with those of the alpha-diversity indexes.
Discussion
Chronic pulmonary colonization with recurrent infective exacerbations, caused by intercur-
rent bacterial, viral and/or fungal infections, produces an irreversible decline in lung function
and early death in CF patients [1,7]. Although a diversity of bacterial species can be isolated
from the CF airways, P. aeruginosa is the most common CF pathogen able to develop chronic
infections with acute exacerbations [1,31,32]. Once established, chronic P. aeruginosa infec-
tions are difficult to treat with antibiotics and the pathogen is virtually never eradicated due to
biofilm formation [31]. Furthermore, P. aeruginosa biofilm may interact with fungi, displaying
an increase in mutability in mixed biofilms [33,34]. P. aeruginosa consortium is also modified
according to a Climax/Attack model when exacerbation occurred [3,4]. In this model, fermen-
tative anaerobes are hypothesized to be the core members of the Attack Community and
responsible for exacerbation [4]. In this context, analyzing microbial community of CF respi-
ratory tract by using HTS coupled with PMA-pretreatment may facilitate the detection of
both viable bacteria (including obligate anaerobes) and fungi potentially involved in the
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exacerbation, without underestimating or overestimating DNA quantifications and microbial
community compositions.
While PMA-pretreatment has been combined with various molecular techniques and suc-
cessfully applied for discriminating between living and dead cells in microbiology [6,8,10–
17,35], it has been combined to pyrosequencing in only few studies to analyze the bacterial
community of environmental and human samples [6,11–15]. Given the importance of detect-
ing the whole viable members at metacommunity level, we studied both respiratory myco-
biome and bacteriome of CF patients colonized with P. aeruginosa during exacerbation using
Fig 4. Effect of PMA on the composition of bacteriome of each sample. (A): Relative abundance of
bacterial genera of each sample (“yes” or “no” indicates the samples with or without PMA-pretreatment). (B):
PCA plot of the first two components of bacteriome of samples with and without PMA-pretreatment. Each
marker represents treatment conditions (filled triangle symbols PMA-treated samples, filled square symbols
untreated samples). Each color represents a given sputum sample (G040.I: light blue; G040.II: aqua; G040.
III: dark blue; G088.I: yellow green; G088.II: chartreuse; G088.III: dark green; G172.II: orange; G172.III: dark
orange; G014.I: grey; G014.II: dark grey; G014.III: black; G176.I: red; G176.II: firebrick; G176.III: dark red).
doi:10.1371/journal.pone.0168860.g004
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Fig 5. Effect of PMA on the composition of mycobiome of each sample. (A): Relative abundance of
fungal genera of each sample (“yes” or “no” indicates the samples with or without PMA-pretreatment). (B):
PCA plot of the first two components of mycobiome of samples with and without PMA-pretreatment. Each
marker represents treatment conditions (filled triangle symbols PMA-treated samples, filled square symbols
untreated samples). Each color represents a given sputum sample (G040.III: dark blue; G088.II: chartreuse;
G088.III: dark green; G172.I: yellow; G172.II: orange; G172.III: dark orange; G014.II: dark grey; G014.III:
black; G176.II: firebrick; G176.III: dark red).
doi:10.1371/journal.pone.0168860.g005
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PMA-pretreatment combined with HTS. Since the mycobiome in general and the lung myco-
biome in particular have not been fully investigated [36], this study provides the first opportu-
nity to focus on the PMA-pretreatment effect on this understudied eukaryotic community and
its co-presence with the bacteriome in human airways during acute pulmonary exacerbation.
Apart from Pseudomonas identified as dominant bacterial genus (in agreement with our
selection criterion of patients chronically colonized with P. aeruginosa), our results (Fig 3A)
confirmed the core taxa of bacteria in CF respiratory microbiome previously described (for
review: [5]). The 9 most abundant genera contributed 94.4% of the total number of sequences
while the rest of more than a hundred genera contributed only a small proportion of the total
OTU number (Fig 4A). Several bacterial species detected in the CF respiratory microbiome
here were also considered as the most frequent oral commensal bacteria such as Streptococcus,
Prevotella, Porphyromonas, Rothia, Tannerella, Fusobacterium,. . . This result confirmed the
close relation between respiratory and buccal microbiotas due to microaspirations of salivary
and potentially explained by the neutral dispersion model recently proposed [37–39]. In addi-
tion regarding the co-presence of Pseudomonas and oral commensal bacteria, there is recent
evidences showing that the oral commensal streptococci could modulate the growth of Pseudo-
monas in CF disease condition [40].
Table 1. Abundance and α-diversity comparison of bacteriome and mycobiome between PMA-pretreated and untreated samples.
Paired sputum samples All populations Abundant population ( 1%) Intermediate population (<1%)
*PMA-treated Un-treated μp PMA-treated Un-treated p PMA-treated Un-treated p
Bacteriome analysis (Number of paired samples = 14):
**Total number of reads 28280 ±14356 26278 ±11194 0.8 27617 ±13955 25591 ±10873 0.8 663 ±538 686 ±490 0.9
Richness 20 ±8 22 ±11 0.3 6 ±3 6 ±3 1 13 ±7 16 ±9 0.3
Shannon index 1.2 ±0.6 1.2 ±0.6 0.6 1.1 ±0.6 1.1 ±0.6 0.7 1.8 ±0.6 2.0 ±0.6 0.06
Simpson index 0.5 ±0.3 0.5 ±0.2 0.9 0.5 ±0.3 0.5 ±0.3 0.7 0.8 ±0.2 0.8 ±0.1 0.03
Mycobiome analysis (Number of paired samples = 10):
Total number of reads 36618 ±44508 28910 ±36879 0.9 36286 ±43812 28637 ±36386 0.9 332 ±763 273 ±741 0.5
Richness 9 ±6 12 ±7 0.9 6 ±4 8 ±4 0.2 3 ±3 4 ±5 0.7
Shannon index 0.7 ±0.5 0.7 ±0.5 0.9 0.6 ±0.5 0.6 ±0.5 0.8 0.6 ±0.6 0.4 ±0.3 0.8
Simpson index 0.3 ±0.3 0.3 ±0.2 0.9 0.3 ±0.3 0.3 ±0.2 0.9 0.3 ±0.3 0.4 ±0.3 0.7
*PMA, propidium monoazide;
μp: p value (significant p value is bolded);
**Total number of reads and all diversity index expressed as mean and standard deviation.
doi:10.1371/journal.pone.0168860.t001
Table 2. p-values and r-values of similarity analysis (one-way ANOSIM) of the bacterial and fungal OTU data.
OTU data Population and sub-populations ap-values br-values
Bacteriome Global population 0.52 -0.011
Abundant population 0.52 -0.010
Intermediate population 0.97 -0.066
Mycobiome Global population 0.84 -0.062
Abundant population 0.84 -0.062
Intermediate population 0.56 -0.009
a p- values indicate the significant differences between PMA-treated and untreated groups;
b r-values indicate dissimilarity between groups as follow: the higher the r-value is, the more dissimilar the compared groups are.
doi:10.1371/journal.pone.0168860.t002
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Similar to bacteriome results, 3 fungal genera accounted for 94.7% of the total number of
fungal OTUs. Among them, Candida genus (including Candida albicans (52.3%)) was the
dominant genus of the CF respiratory mycobiome in our study (Figs 3B and 5A). C. albicans
has been frequently isolated with high prevalence in CF sputa, even if its role in pathogenesis
and clinical CF evolution is still matter of debate (for review: [36,41]). There is also evidence
showing the co-presence of C. albicans and P. aeruginosa in patients’ respiratory tract as an
opportunistic damaging association [33]. The remaining fungal genera represented a limited
number of OTUs, and confirmed the core taxa of lung mycobiome previously described
[25,42–44]. Similar to bacteriome analysis, the high abundance of Candida and Saccharomy-
cetes observed here might also refer to the overlap with the buccal mycobiota in agreement
with published data [37–39]. Interestingly, our study identified an important proportion of
Nakaseomyces delphensis (11.3%) in 7 of total 20 samples from 3 out of the 5 patients. This cul-
tivable non-pathogenic yeast is closely related to Candida glabrata [45]. To our knowledge, it
has never been detected in human respiratory tract. These results underline the large exposure
of lungs to environmental microorganisms that may play a role in chronic respiratory diseases
such as CF, and highlight the importance of analyzing the whole respiratory microbiota, which
could be a reservoir of diverse microorganisms yet to be identified or yet to be classified as
pathogens in CF (such as C. albicans).
As expected, PMA-pretreatment reduced significantly the amplifiable amount of P. aerugi-
nosa DNA and the number of viable cells (Fig 1), in agreement with patient treatment and
published data [6,17]. This result is also compatible with the ability of P. aeruginosa to form
biofilms that contain a higher proportion of dead cells, and are observed in lungs of CF
patients chronically colonized with P. aeruginosa as our patient population [6,17,35]. As OTU
numbers were slightly higher (Table 1) and the mean length of sequencing reads was shorter
in PMA-treated samples than in untreated ones, we could refer to some limitations of the
PMA-treatment technique recently described [13,46,47]. Various factors affecting the influ-
ence of PMA treatment on the results of both qPCR and HTS (type of samples, PMA concen-
tration, PMA incubation time, light source and exposure time, length of target gene, pH) have
been proposed [13,46,47]. We principally followed the steps that were in agreement with an
optimal effect of PMA-pretreatment [16,17]. The estimated numbers of viable cells in our sam-
ples were more than 107 cells/ml, in agreement with the cutoff of 105 cells/ml recently pro-
posed to get the most adequate effect of PMA-treatment [35]. Furthermore, the mean length
(>300 bp) of sequencing reads from both PMA-treated and untreated samples was long
enough to show an accurate detection of viable cells [13]. The use of multiple viability filters
(sample treatment with DNase/Proteinase K or metabolic and enzyme activity estimations)
has also been suggested [11].
As the present study has some limitations such as a modest sample size (15 samples from
CF patients with acute pulmonary exacerbation, without a control group composed of CF
patients clinically stable) or the absence of mycology culture records that have limited the data
analysis, further studies are now warranted to fully evaluate the efficiency of PMA coupled
with HTS.
Besides, the "rare” or “intermediate” population has recently become an emerging concept
in ecology, which has been particularly studied in sea-water samples [27,28,48,49]. Despite dif-
ferent cutoffs used to differentiate the minority taxa (“rare” to “intermediate” taxa), all these
studies have shown that minority populations vary more than majority ones and that minority
taxa play a crucial role in the ecosystem stability [27,28,48,49]. We observed a significant dif-
ference in the diversity of intermediate bacterial populations between the two groups of sam-
ples (Table 1). This result is in agreement with Rogers et al.’s study which also evaluated the
effect of PMA-treatment on P. aeruginosa abundance through qPCR and on the diversity of
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the lung bacteriome from CF patients who were judged to be clinically stable at the sampling
time [6]. While Rogers et al. found that PMA-treatment resulted in an increase in community
evenness driven by an increase in diversity of rare community members, we identified a
decrease in community diversity of intermediate population. Similar to this study, and despite
the two different types of CF populations, our results suggest that there was no significant dif-
ference in the entire bacterial community but PMA-pretreatment could significantly influence
the apparent composition of “satellite” taxon groups analyzed by HTS. Several other studies
using HTS compared the bacterial profiles of PMA-treated and untreated environmental
samples and showed significant changes in the bacteriome structure [11–14]. Whereas
Vaishampayan and colleagues [12] demonstrated a difference in the bacteriome structure of
environmental samples with and without PMA-pretreatment using PCA, we found both
PMA-treated and untreated samples situated virtually next to each other (Fig 4B), in agree-
ment with Exterkate and colleagues’ results, studying oral cavity samples [14].
Regarding the mycobiome, we could not establish any significant difference of abundance
or biodiversity between PMA-treated and untreated samples (Table 1). Despite some changes
in the mycobiota compositions (Fig 5A and S1 Fig), no significant difference in both abundant
and intermediate populations was observed. To the best of our knowledge, this is the first
study focusing on the effect of PMA with regard to airway mycobiome characterization by
HTS, which limits the comparison and discussion of our findings. However, PMA-treatment
has been recently coupled with HTS to investigate the fungal burden of room dust samples
[15]. The authors found remarkable differences between the PMA-treated and untreated sam-
ples, and indicated the presence of a large proportion of pathogenic fungal genera such as
Aspergillus, including A. fumigatus which represents the most frequent pathogenic mold iso-
lated in CF respiratory samples [41]. We identified Candida, Malassezia, Alternaria, and Fusar-
ium, but OTUs belonging to Aspergillus genus were not isolated. This result could be explained
by some bias in DNA extraction or amplification. As we were able to amplify DNA from other
phylogenetically close filamentous genera such as Fusarium, DNA extraction method should
be sufficient to breakdown fungal cell walls. The primers we used were shown to be highly effi-
cient for amplification of diverse fungal species including those of the Ascomycota, Basidiomy-
cota and non-Dikarya [19]. This suggests that A. fumigatus was indeed not present in our
samples, as confirmed with the Aspergillus qPCR results.
Considering the co-evolution and co–exclusion of core taxa, our results suggest that PMA-
pretreatment explains better the physiopathology of these core taxa and their interactions in
the CF lung environment. We report a proportion of Pseudomonas increasing from 27.8% to
41.4% of total reads in the PMA-treated group, in agreement with Rogers et al.’s results [6]. In
parallel, OTUs of Streptococcus, Azomonas, and Candida genera decreased (Fig 3). These
microbial proportions modified between the PMA-treated and untreated groups may reflect
the behaviors of microbial communities within CF lungs: (i) Decrease in pH, low concentra-
tion in oxygen, high level of mucus, and bioavailability of metabolites such as alanine and lac-
tate represent optimal conditions for P. aeruginosa growth, especially as biofilm consortium
that PMA-treatment put prominently by differentiating viable to dead cells (for review: [39].
(ii) By providing an appropriate competitive niche for Pseudomonas genus, other genera such
as Streptococcus and Azomonas may lose their survival advantages in CF lungs, a hypothesis in
agreement with Filkins et al.’s analysis [50] which concluded that Streptococcus may play a cen-
tral role in the stability of the lung microbiome. (iii) At the cross-kingdom communication
level, lung interactions between Candida (especially C. albicans) and Pseudomonas or Strepto-
coccus have been described [33,51,52]. There is evidence that Candida and Pseudomonas coex-
ist in biofilms with both negative and positive association. Roux et al. [51] showed that rats
inoculated with P. aeruginosa developed pneumonia only in the presence of viable C. albicans.
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P. aeruginosa secretes phenazines which are toxic to yeast and hyphal forms of C. albicans. It
also produces a quorum-sensing which is similar to farnesol, a molecule secreted by C. albicans
to regulate hyphal growth (for review: [53]). All these interactions may contribute to the for-
mation of a specific microbiome in CF patients’ lungs able to face host-immune response and
antimicrobial treatment. Our findings add support to the complex interaction especially dur-
ing exacerbation between typical pathogens and microbiota, such as the association between P.
aeruginosa and anaerobes, and/or fungi.
Conclusion
The rationale of this study was whether PMA-pretreatment had an effect on the measured bac-
terial and fungal compositions, presumably resulting in a more accurate account of the viable
microorganisms in CF lung microbiota. While culture-independent methods such as HTS are
not able to discriminate dead from viable cells, culture dependent methods allow us to identify
viable microorganisms, but not non-cultivable ones. PMA combined with HTS is therefore
believed to be a worthy perspective solution that allowed us to show that during acute exacer-
bation the CF airway microbiome is diverse and largely made up of viable community mem-
bers. According to our results and published ones [6], PMA-treatment highlights changes in
the relative abundance of OTUs in the CF sputum samples which can help for respiratory
microbiota analysis without overestimating the abundance of each viable microorganism.
Due to its time consumption and cost, this technique should be limited to cases that are diffi-
cult to manage. Improvement of the clinical status is the main objective when CF patients
chronically colonized with P. aeruginosa receive antibiotic treatment to face acute exacerba-
tion. Therefore, including PMA-pretreatment in the HTS sample analysis may be considered
as a second line diagnostic tool used when the patient does not respond well to antimicrobial
treatment, and/or when biofilm consortium is suspected; these two clinical situations could
benefit from an accurate estimation of the “core” or abundant viable community members
during exacerbation.
Further studies combining HTS analysis to viable microorganism differentiations are war-
ranted to open new strategies for CF patient management. Given our results and the ability of
filamentous fungi to cause acute pulmonary exacerbation, lung mycobiota analysis have to be
included in these studies to give a realistic composition of the CF lung microbial community
that may shape a local response and explain a specific clinical evolution.
Supporting Information
S1 Fig. Individual comparison of P. aeruginosa abundances estimated by qPCR in PMA-
treated (circle in black) and untreated (circle in red) samples.
(TIF)
S2 Fig. Dendrograms representing the similarity between the composition of bacteriome
and mycobiome from individual samples in all taxa. Clustering is based on Bray Curtis simi-
larity distance matrix (bootstrap 10000 replicates). Bootstrap values (in percentages) are given
at the nodes.
(TIF)
S3 Fig. Dendrograms representing the similarity between the composition of bacteriome
and mycobiome from individual samples in abundant taxa (1%). Clustering is based on
Bray Curtis similarity distance matrix (bootstrap 10000 replicates). Bootstrap values (in per-
centages) are given at the nodes.
(TIF)
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S4 Fig. Dendrograms representing the similarity between the composition of bacteriome
and mycobiome from individual samples in intermediate taxa (<1%). Clustering is based
on Bray Curtis similarity distance matrix (bootstrap 10000 replicates). Bootstrap values (in
percentages) are given at the nodes.
(TIF)
S1 Table. Repartition of reads at the bacterial and fungal genus level for each sputum sam-
ple treated and un-treated with PMA.
(XLSX)
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